***Background.*** Randomized trials indicate superior effectiveness of live attenuated influenza vaccine (LAIV) compared to inactivated influenza vaccines (IIV) in children aged 2 -6 years. We compared relative effectiveness of LAIV versus IIV in preventing medically attended influenza illness in children 2--18 years enrolled in an observational study of influenza vaccine effectiveness (VE) over two seasons.

***Methods.*** We analyzed data from 1468 children aged 2-18 years, considered fully vaccinated with either LAIV or IIV, who presented for treatment of acute respiratory illnesses (ARI) during the 2011-12 or 2012-13 influenza seasons. Specimens from participants were tested for influenza infection by real-time reverse-transcription PCR. Relative VE was calculated by comparing LAIV versus IIV receipt in those patients who tested positive for influenza and those who tested negative and calculated as 100 x (1- adjusted odds ratio) in logistic regression models adjusted for age, race/ethnicity, sex, subjective health status, presence of high risk conditions, enrollment site, interval from illness onset to enrollment (days), and week of enrollment.

***Results.*** 576 fully vaccinated children aged 2-18 years were enrolled during medically attended ARI episodes in 2011-12 and 892 in 2012-13. In 2011-12, among 72 (13%) children with laboratory-confirmed influenza, 12 (17%) had received LAIV and 60 (83%) IIV; among 504 influenza test-negative children, 100 (20%) had received LAIV and 404 (80%) IIV. Relative effectiveness of LAIV vs. IIV in 2011-12 was 4% (95% CI, -106, 55). In 2012-13, among 289 (32%) children with laboratory confirmed influenza, 65 (22%) had received LAIV and 224 (78%) IIV; among 603 influenza test-negative children, 148 (25%) had received LAIV and 455 (75%) IIV. Relative effectiveness in 2012-13 was 4% (95% CI, -40, 34). In children aged 2--8 years, relative effectiveness of LAIV vs. IIV was 43% (95% CI: -80, 82) in 2011-12 and 35% (95% CI -8, 61) in 2012-13. In children aged 9--18 years, relative effectiveness of LAIV vs. IIV was -16% (95% CI, -277, 64) in 2011-12 and -21%, (95% CI, -134, 38) in 2012-13.

***Conclusion.*** We observed nonsignificant results that did not indicate a difference in effectiveness of LAIV compared to IIV in preventing medically attended influenza illness in children and adolescents.
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